| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Grant revenue | 209 | 290 | 342 | 369 |
| Research and development | 20,339 | 16,620 | 14,332 | 12,028 |
| General and administrative | 7,731 | 7,709 | 7,842 | 6,975 |
| Total operating expenses | 28,070 | 24,329 | 22,174 | 19,003 |
| Operating loss | -27,861 | -24,039 | -21,832 | -18,634 |
| Interest income | 1,957 | 2,159 | 2,384 | 3,581 |
| Interest and other expense | 65 | 119 | 128 | 69 |
| Other income from a related party (note 3) | 0 | 0 | 1,400 | - |
| Equity in loss of affiliate | 0 | 0 | -1 | - |
| Total non-operating income, net | 1,892 | 2,040 | 3,655 | 3,512 |
| Net loss from continuing operations | -25,969 | -21,999 | -18,177 | -15,122 |
| Net loss before deferred income tax benefit | - | - | - | -15,122 |
| Net gain (loss) from discontinued operations | 0 | 514 | - | - |
| Net loss | -25,969 | -21,485 | -18,177 | -15,122 |
| Basic and diluted (in shares) | 74,296,000 | 74,235,000 | 72,357,000 | 70,629,000 |
| Basic loss per share | -0.35 | -0.29 | -0.25 | -0.21 |
| Diluted loss per share | -0.35 | -0.29 | -0.25 | -0.21 |
| Weighted average number of shares outstanding, diluted, total | 74,296,000 | 74,235,000 | 72,357,000 | 70,629,000 |
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)